Foghorn Therapeutics Inc.: financial statements

FHTXNASDAQHealthcare · Pharmaceutical Preparations

Price

$2.07

November 13, 2026Market cap $122M

What Ploutos Investor adds for Foghorn Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

Financial statements

Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.

2023–2025 fiscal years

Click a line to see it on the chart.

Revenue

-4.9% a year over 2 years

Line202320242025Average a year
Revenue $34M$23M$31M-4.9%
Operating income -$108M-$103M-$86M
Net income -$98M-$87M-$74M
Earnings per share -$2.34-$1.58-$1.18
Earnings per share, basic -$2.34-$1.58-$1.18
Margins
Operating margin -315.9%-454.3%-279.5%
Net margin -288.2%-383.2%-240.3%

Financial statements

FHTX's revenue, profits and cash flows from 2020 to 2022, 3 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.

Debt and obligations

What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.

$41M Leases0.0% Effective tax rate

Leases

Dec 31, 2025

Operating leases

$41M

Finance leases

–

The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing

From the statutory to the effective tax rate, 2025

Dec 31, 2025

Statutory rate

21.0%

Effective rate

0.0%

-21.0 pts

The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.

Statutory rate

21.0%

Change in valuation allowance

-21.3 pts

Difference the filing does not itemize

+0.3 pts

Effective rate

0.0%

One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing

The full analysis

What do Foghorn Therapeutics's filings show?

These are Foghorn Therapeutics's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about FHTX's financials

Didn't find what you were looking for?

Ask us
How much revenue did FHTX have in 2025?

Foghorn Therapeutics had revenue of $31M and net income of -$74M in fiscal 2025, a net margin of -240.3%.

How much debt does FHTX have?

On December 31, 2025 Foghorn Therapeutics had total assets of $198M, debt of – and shareholders' equity of -$109M.

How much free cash flow does FHTX have?

In fiscal 2025 Foghorn Therapeutics had cash from operations of -$86M and spent $50.0K on capital expenditure, leaving -$86M of free cash flow.

Where are the figures from?

From Foghorn Therapeutics Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.